Fosun Pharma

Conjustar, a protein-conjugated medicine developer that has rapidly built a robust R&D pipeline through a combination of introduction and independent research and development. it delivers more effective and safer new cancer therapy options to the majority of cancer patients.

Fosun Kite Biotechnology is a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd and Kite Pharma, specializing in the development of immune cell therapy products. The company is dedicated to creating innovative pharmaceutical solutions for cancer treatment, specifically targeting B-cell lymphomas and leukemias. Through its robust research capabilities, Fosun Kite Biotechnology is focused on advancing products such as axicabtagene ciloleucel and kite-439, with the goal of producing high-quality medicines for medical industry clients.

VerImmune, based in Baltimore, Maryland, is an Immuno-Oncology company focused on developing innovative cancer therapies through its proprietary technology known as Anti-tumor Immune Redirection Virus-inspired Particles (AIR-ViPs). This first-in-class approach aims to harness and redirect pre-existing immune memory from pathogenic infections or childhood vaccines towards tumors. By doing so, VerImmune seeks to offer a transformative treatment option for patients with various types of cancers, especially those facing treatment resistance or limited therapeutic choices. The company's goal is to provide a low-toxicity solution that delivers durable benefits across a broad spectrum of cancer types.

Bianjie.AI is a company focused on advancing blockchain technology and its applications. It specializes in the development of a global Web 3.0 internet infrastructure platform that serves as a technological foundation for distributed business ecosystems. The company offers a range of products, including blockchain development middleware, a service framework, and a decentralized data exchange network for analysis. Additionally, Bianjie.AI has created a medical knowledge base and a delivery vehicle for medical information that utilizes blockchain technology to facilitate data exchange. The firm is also skilled in interchain technology, non-fungible tokens, big data, and privacy computing, positioning itself as a key player in the evolving landscape of blockchain solutions.

Scolioscan is a developer and provider of advanced three-dimensional ultrasound imaging technology aimed at detecting and preventing musculoskeletal chronic diseases, particularly scoliosis. The company specializes in creating equipment and solutions that facilitate safe scoliosis assessments without the use of radiation. Scolioscan's offerings include 3D medical ultrasound imaging tools that are applicable in screening, diagnosing, tracking disease progression, and evaluating treatment outcomes. By providing orthopedics, rehabilitation, and sports medicine professionals with accurate and radiation-free assessment protocols, Scolioscan enhances the quality of care for patients with scoliosis and related conditions. The company's commitment to research and development in medical imaging technology underpins its mission to improve healthcare outcomes in musculoskeletal health.

Primelink Bio is a biotechnology firm focused on developing advanced drug delivery systems, particularly through antibody-drug conjugate (ADC) technology. The company employs a flexible and modular platform to synthesize a diverse library of ADC drug candidates. By utilizing bioconjugation technology, Primelink Bio aims to identify optimal drug compositions tailored for specific targets, thereby enhancing treatment effectiveness for cancer patients. Through its innovative approach, the firm seeks to improve therapeutic outcomes and contribute significantly to the field of cancer treatment.

Porton Advanced Solutions (Porton Advanced) is a CDMO specializing in Cell and Gene Therapy (CGT). To address clients' therapeutic product demands at the pre-clinical, clinical, and commercial stages, the firm offers end-to-end process development (PD), analytical development (AD), GMP manufacturing, and testing services.

Fosun Xingmai is a scientific and technological innovation-oriented enterprise focusing on the research and development, production and sales of medical imaging and pathological artificial intelligence software and digital solutions. Its products mainly analyze medical images through the use of artificial intelligence technology.

ZuriMED Technologies AG is a Swiss-based company specializing in orthopedic biomechanics and sports medicine. Founded in 2015 and originating as a spin-off from the University of Zurich and ETH Zurich, the company focuses on developing innovative medical technologies for soft tissue repair. One of its notable products is the BTB-Converter, a device designed for surgical knee ligament reconstruction. ZuriMED has also introduced the Surgical-Fiberlock technology, which functions like a surgical "sewing" machine to mechanically interlock medical patch fibers into soft tissues. This advanced technique allows surgeons to securely attach patches more quickly and confidently, improving the overall efficiency of procedures like anterior cruciate ligament reconstruction. By minimizing the need for interference screws and reducing the number of surgical steps, ZuriMED aims to enhance patient recovery times and reduce discomfort.

OncoCare Cancer Centre is the largest private oncology practice in Singapore, offers specialized facilities to care for cancer patients.

UniXell develops cell therapies for the treatment of cancer and neurodegenerative disorders.

UniXell Biotechnology is a developer of cell therapy focused on addressing unmet medical needs through human pluripotent stem cell technology. The company specializes in creating innovative treatments for neurodegenerative diseases, rare diseases, and tumors. Utilizing its proprietary platforms, UniXell Biotechnology has advanced capabilities in stem cell preparation, cultivation, differentiation, and gene editing. Key technologies include reprogramming techniques, stem cell differentiation, SISBAR pedigree tracing, and high-precision gene editing, which collectively aim to provide effective therapeutic solutions for patients suffering from challenging medical conditions.

Insilico Medicine, Inc. is a biotechnology company that leverages artificial intelligence (AI) to transform drug discovery, biomarker development, and aging research. Founded in 2014 and based in Baltimore, Maryland, the company has established itself as a pioneer in applying advanced AI techniques, such as generative adversarial networks and reinforcement learning, to create novel molecular structures for various diseases, including cancer and age-related conditions. Insilico Medicine operates an integrated platform that covers all stages of drug discovery, from initial research to clinical trial analysis. Its projects include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, a platform focused on aging predictors. The company also pursues internal drug discovery initiatives targeting diseases like Alzheimer's and Parkinson's, and has partnered with Life Extension to produce nutraceutical products utilizing deep learning and bioinformatics. Additionally, Insilico Medicine provides consumer applications aimed at enhancing health and longevity.

Antejin Biotech specializes in developing rabies immunogenic conjugate useful for preparing rabies conjugate vaccine.

Jianjia Robot develops a hard tissue surgical robot platform promoting technological progress in the field of surgery at home and abroad. Jianjia Robot's orthopedic joint surgical robot, ARTHROBOT, can cover both hip and knee joints, breaking the long-term monopoly of imported surgical robots in this field.

Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.

MitrAssist is a medical device company focused on addressing mitral valve regurgitation (MR) through an innovative and minimally invasive approach. The company has developed a proprietary mitral valve implant that complements the natural mitral valve rather than replacing or repairing it. This unique "valve-in-valve" technique enhances the functionality of the existing valve, providing an effective treatment option for patients suffering from MR. MitrAssist's implant is designed to address the challenges associated with MR, offering a solution that surpasses current minimally invasive alternatives. By prioritizing patient health and comfort, MitrAssist aims to significantly improve treatment outcomes for individuals with this condition.

Jianjia Robot develops a hard tissue surgical robot platform promoting technological progress in the field of surgery at home and abroad. Jianjia Robot's orthopedic joint surgical robot, ARTHROBOT, can cover both hip and knee joints, breaking the long-term monopoly of imported surgical robots in this field.

Fosun Kite Biotechnology is a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd and Kite Pharma, specializing in the development of immune cell therapy products. The company is dedicated to creating innovative pharmaceutical solutions for cancer treatment, specifically targeting B-cell lymphomas and leukemias. Through its robust research capabilities, Fosun Kite Biotechnology is focused on advancing products such as axicabtagene ciloleucel and kite-439, with the goal of producing high-quality medicines for medical industry clients.

Hinova Pharmaceuticals Inc. is a drug discovery and development company based in Chengdu, China, with additional branches in Hong Kong, Texas, and Australia. Established in 2013, the company specializes in the research and manufacturing of innovative medicines to address unmet medical needs, particularly in oncology and metabolic diseases. Utilizing advanced technology platforms such as deuterium and PROTAC, Hinova develops both Best-in-class and First-in-class drugs. Its product pipeline includes the HC-1119 androgen receptor antagonist and HC-1102 androgen receptor inhibitors, which target advanced prostate cancer and breast cancer. The company's commitment lies in providing safe, effective, and affordable treatments while retaining global rights and interests in its drug portfolio.

Yudo Bio provides biopharmaceutical products. It has its headquarters in Shanghai in China.

EOS Imaging SA is a medical technology company based in Paris, France, specializing in low-dose 2D/3D imaging and software solutions for osteo-articular conditions and orthopedic surgeries. The company develops and markets the EOS imaging system, which produces full-body, stereo-radiographic images of patients in functional positions, tailored to the specific needs of orthopedic surgeons and radiologists. Its product offerings include EOSedge, a high-quality X-ray system, sterEOS, a 3D modeling workstation for precise skeletal analysis, and EOSapps, online surgical planning solutions based on real-time imaging. Additionally, EOS Imaging creates planning software for knee and hip surgeries and manufactures patient-specific cutting guides for orthopedic procedures. The company operates globally, with a presence in Europe, the Middle East, Africa, North America, the Asia-Pacific, and Latin America, and has obtained marketing authorization for its systems in 48 countries. Founded in 1989, EOS Imaging was previously known as biospace med before rebranding in 2010.

Glycotest Diagnostics develops non-invasive blood tests for early detection of liver cancers and fibrosis-cirrhosis, benefiting at-risk populations with viral hepatitis or fatty liver disease. Its proprietary serum biomarker technology enables novel clinical laboratory testing services.

Butterfly Network is a medical technology company developing handheld ultrasound systems that aim to democratize imaging and expand access to care. Its flagship device, a single-probe handheld system powered by Ultrasound-on-Chip semiconductor technology, enables whole-body diagnostic imaging with cloud-connected software and a mobile application, allowing clinicians to acquire, store, and analyze ultrasound data in real time. The platform supports workflow integration for hospitals and outpatient settings, and can image vascular, cardiac, abdominal, urological, fetal, gynecological, and musculoskeletal regions. The company envisions improving early detection and remote management of health conditions by enabling pocket-sized imaging capability and scalable ultrasound programs across healthcare facilities. Butterfly Network was founded with a mission to advance global health equity by increasing ultrasound access worldwide. The technology combines a compact hardware device with software to streamline acquisition, interpretation, and sharing of ultrasound information in clinical workflows.

Shanghai Fushoukang Rehabilitative Home Nursing Services specializes in in-home rehabilitation and nursing care for the elderly, as well as individuals who are weak, sick, or disabled. Founded in 2011 and headquartered in Shanghai, the company offers a range of services including home care, community care, nursing care, and bathing assistance. By focusing on the needs of vulnerable populations, Fushoukang aims to enhance the quality of life for its clients through personalized care in the comfort of their own homes.

Yidebang is a Beijing-based healthcare software developer, which provides management solution, drug supply, hierarchical diagnosis and treatment and other supporting medical services for basic-level clinics in China.

Shanghai Henlius Biotech, Inc. is a biopharmaceutical company based in Shanghai, China, specializing in the research, development, production, and commercialization of biologics, particularly monoclonal antibody (mAb) biosimilars and novel therapies. Founded in 2010, the company focuses on oncology and autoimmune diseases, offering products such as HLX01, a biosimilar for treating non-Hodgkin lymphoma. Henlius is actively advancing its pipeline, with multiple products under review for regulatory approval, alongside conducting numerous clinical studies for various therapies. The company collaborates with partners, including agreements to develop treatments for COVID-19 and eye diseases. Shanghai Henlius Biotech is a joint venture between Shanghai Fosun Pharmaceutical and Henlius Biopharmaceuticals, established in 2009, and operates out of the Shanghai Caohejing High-Technology Park.

Shanghai LinkedCare Information Technology Co., Ltd. is a company that specializes in developing oral intelligence management software and integrated management systems tailored for dental clinics and medical beauty institutions. Founded in 2015 and based in Shanghai, the company offers a comprehensive dental cloud management solution that includes features such as electronic signatures, member management, treatment planning, clinic analysis, chain management, and inventory oversight. Additionally, it provides medical beauty cloud management solutions, encompassing marketing tools, member management, cashier systems, appointment scheduling, and analytical management. LinkedCare aims to fully automate the digital operations of consumer medical institutions, promoting standardization in management and treatment, enhancing marketing capabilities, and facilitating mobile office solutions. Through its services, the company helps institutions improve operational efficiency, increase revenue, and manage risks effectively.

Groupe TRIDEM Pharma is a pharmaceutical distribution and promotion company based in Escalquens, France, with a focus on the African and Middle Eastern markets. Established in 1986, the firm specializes in the distribution of a wide range of pharmaceutical and para-pharmaceutical products, including tablets, syringes, balms, gels, creams, and soaps. In addition to facilitating product distribution, TRIDEM Pharma offers outsourcing services, licensing, marketing, and training programs for medical and pharmaceutical sales representatives. The company is dedicated to helping its clients manage risks associated with medical products through its pharmacovigilance processes, thereby ensuring the safe and effective use of pharmaceuticals in the regions it serves.

CytoChip Inc. is a company specializing in the design and manufacture of in vitro diagnostic devices. Founded in 2014 and headquartered in Irvine, California, CytoChip focuses on transforming point-of-care diagnostics through innovative technologies. Its flagship product, the CHIPNOW SYSTEM, facilitates in vitro diagnostics for various tests, including complete blood counts, lipid panels, and glucose monitoring. In conjunction with CHIPNOW CARTRIDGES, which utilize advanced microfluidic design, the system enables precise testing of lymphocyte counts and other cellular characterizations from minimal blood samples. CytoChip is dedicated to making reliable and affordable diagnostics accessible, with a particular emphasis on empowering healthcare providers and patients alike. The company also collaborates with leading hospitals to advance its clinical validation and innovation efforts.

Breas Medical AB specializes in designing, developing, and manufacturing homecare ventilation and sleep therapy products for both adult and pediatric patients with respiratory issues. Founded in 1991 and based in Molnlycke, Sweden, the company offers a range of medical devices, including continuous positive airway pressure devices, pressure control and support devices, life-support ventilators, and sleep apnea therapy devices. These products are intended to assist patients suffering from conditions like neuromuscular disorders, anatomical defects, and pulmonary diseases. Breas Medical also provides clinical services and distributes its products globally through a network of trained distributors and an online store. The company is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Sinopharm Online has a pharmaceutical retail platform to provide users with online medication consultation, medical and health management consulting services, etc. The main sales cover Chinese and Western medicines and health products. , medical equipment, Chinese medicine

Ambrx, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the development of engineered precision biologics through an expanded genetic code technology platform. This innovative approach enables the incorporation of synthetic amino acids into proteins, facilitating the creation of next-generation therapeutics. Ambrx focuses on various product candidates, including antibody drug conjugates (ADCs), bispecific antibodies, targeted immuno-oncology treatments, and long-acting therapeutic peptides aimed at addressing metabolic and cardiovascular diseases. The company has a robust development pipeline featuring multiple clinical and preclinical programs, with its lead candidate ARX788 among them. Ambrx also collaborates with other organizations, such as MabSpace Biosciences and BeiGene, to enhance its research and development efforts in oncology and other therapeutic areas. Founded in 2003, Ambrx is committed to advancing the efficacy and safety of new biologic therapies for patients.

Gland Pharma is a Hyderabad‑based manufacturer of small‑volume parenterals that develops, produces and markets injectable generic liquid products. Founded in 1978, the company specializes in complex injectables such as heparin sodium, enoxaparin sodium, rocuronium bromide and daptomycin, and offers a broad portfolio that spans anti‑infectives, anesthetics, anti‑coagulants, anti‑malaria, cardiology, gastro‑intestinal, hormonal, fertility, oncology, ophthalmic and other therapeutic areas. It supplies products in vials, ampoules, pre‑filled syringes, lyophilized vials, dry powders, infusions and other formats to regulated markets in the United States, Canada, Europe and Australia, and to other regions worldwide. Gland Pharma also provides contract development and manufacturing services to global partners and is recognized for pioneering heparin technology in India and for its leadership in glycosaminoglycans. The company operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Minneapolis, Minnesota, dedicated to developing innovative treatments for kidney and neurological diseases. The company's lead drug candidate, DM199, is a recombinant human tissue kallikrein-1 protein. It has completed Phase Ib clinical trials for treating moderate to severe chronic kidney disease linked to Type I or Type II diabetes and is undergoing Phase II trials for acute ischemic stroke. DM199 has been administered to nearly 100 patients, demonstrating a safe and well-tolerated profile. Additionally, DiaMedica is developing DMDx, a diagnostic tool to measure human tissue kallikrein-1 levels. The company has a collaboration agreement with Ahon Pharmaceutical Co Ltd. to further develop and commercialize DM199 for acute ischemic stroke. DiaMedica Therapeutics was founded in 2000 and was previously known as DiaMedica Inc. before rebranding in December 2016.

Spirosure is a company focused on the development and commercialization of breath-analysis devices designed for the non-invasive diagnosis and management of chronic diseases, including asthma, chronic obstructive pulmonary disease (COPD), and pulmonary hypertension. By leveraging advanced consumer technologies, such as sensors and algorithms, Spirosure's products enable medical researchers to detect biomarkers in a patient's breath. This capability allows for improved diagnosis and monitoring of respiratory conditions, as well as adherence to asthma-maintenance medications. The company's innovative approach positions it at the forefront of preventative healthcare, providing significant benefits to patients and healthcare providers alike.

Yaoshibang is a Chinese B2B pharmaceutical trading platform that focuses on empowering participants in the out-of-hospital pharmaceutical market. The company serves a diverse range of stakeholders, including pharmaceutical companies, distributors, vendors, pharmacies, and primary healthcare institutions. By leveraging digitalization, Yaoshibang aims to streamline the procurement of pharmaceutical health products and services, ensuring that users can access a wide array of high-quality drugs at fair and transparent prices. The platform transforms traditional pharmaceutical transactions into a digitalized, standardized, and scalable process, enhancing efficiency and safety in the delivery of healthcare products.

Astute Medical, Inc. is a life science tools company focused on improving the diagnosis of high-risk medical conditions through the discovery and development of protein biomarkers. Founded in 2007 and based in San Diego, California, with an additional location in Paris, France, the company specializes in creating novel diagnostic tests that enable rapid diagnosis and risk assessment for conditions such as abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury, and sepsis. Astute Medical's flagship product, NephroCheck, is a single-use cartridge designed to detect biomarkers associated with acute kidney injury, while the Astute140 meter converts the test's fluorescent signal into a single numerical result. The company markets its products primarily in the United States and Europe and operates as a subsidiary of bioMérieux S.A.

Amerigen Pharmaceuticals Limited, founded in 2007 and headquartered in Suzhou, China, specializes in the development, manufacture, and distribution of generic pharmaceutical products, primarily targeting the United States and China. The company operates a US office in central New Jersey, which supports functions such as product and business development, finance, regulatory affairs, and commercial operations. Amerigen's product development efforts are conducted globally, overseen by experienced leadership in research and development, quality assurance, and regulatory compliance. By focusing on high-quality generics, Amerigen aims to serve two of the largest pharmaceutical markets in the world.

Anhui Sunhere Pharmaceutical Excipients Company is a leading manufacturer in the pharmaceutical excipients sector, specializing in the research, development, production, and sales of a variety of excipients used in oral solid preparations. The company offers a range of products, including hypromellose, carmellose calcium, hypromellose phthalate, microcrystalline cellulose, and polyacrylic resin emulsion, which serve as fillers, adhesives, disintegrants, lubricants, and coating materials. As a prominent player in China’s pharmaceutical industry, Anhui Sunhere is dedicated to providing high-quality excipients that support the formulation of effective medical and pharmaceutical products while also offering research and development services to enhance its product offerings.

Check-Cap Ltd. is a clinical-stage medical diagnostics company based in Isfiya, Israel, specializing in the development of innovative solutions for colorectal cancer screening. The company's flagship product, the C-Scan system, is a capsule-based technology that utilizes low-dose X-rays to detect colonic polyps and colorectal cancers without the need for bowel preparation or invasive procedures. The C-Scan system consists of three components: the C-Scan Cap, an ingestible capsule that collects and transmits imaging data; the C-Scan Track, a biocompatible device worn by the patient to track the capsule's movement and record data; and C-Scan View, software designed to process and visualize the captured clinical data. This preparation-free approach is intended to provide accuracy comparable to traditional colonoscopy, with the capsule passing naturally through the gastrointestinal tract. Check-Cap aims to bring its technology to markets in the United States, Europe, Israel, and Japan.

Chindex International, Inc. provides healthcare services in China. The company owns and operates the United Family Healthcare network of private primary care hospitals and affiliated ambulatory clinics in Beijing, Shanghai, Tianjin, and Guangzhou. The company was founded in 1981 and is headquartered in Bethesda, Maryland.

BSC develops a series of software and hardware products. They provide teleconsultation, remote video, remote ECG, telepathology, distance education, and remote ultrasound services.

Saladax Biomedical, Inc. is a precision medicine company based in Bethlehem, Pennsylvania, focused on developing and commercializing diagnostic blood tests that enhance personalized medicine. The company offers a range of products aimed at optimizing drug therapy in psychiatry and oncology. Its MyCare product line includes tests such as MyCare Psychiatry, which helps determine appropriate antipsychotic dosages; MyCare Oncology, which focuses on chemotherapy exposure optimization; and MyCare Neurology for assessing neurological drug effects. Key tests include My5-FU, MyPaclitaxel, MyDocetaxel, and MyImatinib, which are designed to tailor chemotherapy treatments for various cancers. Saladax Biomedical markets its diagnostic solutions to healthcare providers worldwide through both distributors and direct sales, striving to empower physicians to deliver personalized care by ensuring optimal drug dosing. The company has been providing innovative diagnostic solutions for over 15 years.

Shenyang Hongqi Pharmaceutical Co., Ltd., established in 1964 and a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., specializes in the development, production, and distribution of pharmaceutical products, particularly anti-tuberculosis drugs. As a key member of the Chinese Anti Tuberculosis Association, the company is dedicated to combating tuberculosis by providing effective treatment options. Shenyang Hongqi Pharmaceutical is engaged in extensive research and development efforts aimed at enhancing drug efficacy and accessibility, ensuring that patients have access to a diverse range of anti-tuberculosis therapies. The company's focus on innovation underscores its commitment to improving healthcare outcomes for patients worldwide.

Golden Elephant Pharmacy is an online pharmaceutical store.

Hengda Gufen is a shoe and apparel manufacturing and seller company.

Laoniangjiu Catering is a food and beverage company. They offer a business takeaway menu with staple meals, beverages, desserts, delicious soups, and breakfast snacks. They provide chinese-style fast food products that are mainly flavored and can be superimposed on food and beverages.

Salus BioMed is a biomedical company focused on advancing genetic sequencing technology and spatial omics products. It specializes in the development of a DNA sequencing platform that enhances the measurement of gene activity through high-definition spatial transcriptomics. This technology supports users in diagnosing and treating various diseases, positioning Salus BioMed at the forefront of innovation in genomic research and healthcare solutions.